ABSTRACT
<p><b>OBJECTIVE</b>To compare the clinical effects and clinical indications between Mobi-C cervical artificial disc replacement (CADR) and MC+ anterior cervical decompression and fusion(ACDF) in treating cervical spondylosis.</p><p><b>METHODS</b>The clinical data of 100 patients with cervical spondylosis treated ACDF or CADR from June 2009 to June 2015 were retrospectively analyzed. There were 53 males and 47 females, aged from 38 to 70 years old. Among them, 50 cases were treated by ACDF (ACDF group), follow-up time was for 22 to 42 months with an average of (32.24±5.20) months;other 50 cases were treated by CADR (CADR group), follow-up time was for 23 to 48 months with an average of (30.40±5.66) months. Odom criterion was used to evaluate the clinical effects in two groups. JOA score, including sensory function, motor function and bladder function was used to assess the spinal cord function. Preoperative and postoperative responsible intervertebral space heights, cervical curvatures were compared by image data between two groups.</p><p><b>RESULTS</b>All incisions obtained good healing and no serious complications were found. At final follow-up, 30 cases got excellent results, 12 good, 8 fair in ACDF group;and 34 cases got excellent results, 10 good, 6 fair in CADR group;there was no significant difference between two groups(u=4.000, =0.827). At final follow-up, the scores of sensory function and motor function were obviously improved(<0.05), and bladder function had not obviously recovered (>0.05) in two groups;and CADR group in the scores of sensory function and motor function were obviously better than of ACDF group(<0.05). There was no significant difference in preoperative intervertebral space height, cervical curvature between two groups, and at final follow-up both had different recovered. The recovery of CADR group was obviously better than of ACDF group.</p><p><b>CONCLUSIONS</b>CADR can quickly recover normal action for patients and retains the movement. CADR has certain advantages in recovering cervical curvature, improveing sensory function and motor function, but it is not able to completely replace ACDF.</p>
ABSTRACT
In the wake of on-the-spot investigation into Chinese major production bases in Fujian, Zhejiang, Jiangxi, Taiwan, Guangxi and Yunnan provinces, and based on relevant literature, the paper systematically elaborates the current researches of botanical origin, major cultivation type, seedling propagation technique as well as cultivation mode of Jinxianlian. The way of seedling breeding mainly includes aseptic seed culture, in vitro propagation, artificial seed and bioreactor propagation, etc. And the planting model mainly includes protected cultivation modes, bionic wild cultivation modes and pot cultivation modes, etc. Further discussions have also been conducted to tackle significant problems existing in the production process of Jinxianlian, based on personal studies of the authors. It has made considerable contributions for the betterment of Jinxianlian's development and improvement.
ABSTRACT
The current status of the domestic manufacturing and sales markets of Anoectochilus roxburghii were investigated and analyzed in the study. Some problems in the A. roxburghii industry were revealed and a variety of sustainable development countermeasures were also proposed. The main problems of A. roxburghii industry are the lack of protection for wild resources, the lag in the speed of variety breeding, the insufficient research on the quality systems, the low level of industry and product innovation capability, as well as the relatively low market cognition and brand competence. Therefore, strengthening the protection for breeding resources, establishing a dynamic monitoring system, promoting the variety breeding, constructing a propagation system for improved varieties, enhancing the quality of medicinal herbs, accelerating the adjustment of product structure, upgrading the industry technology, strengthening brand competence and expanding the market, will be the effective methods to realize the sustainable development of A. roxburghii industry.
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the therapeutic and adverse reactions of integrative Chinese and Western medicine (ICWM) for treatment of advanced gastric carcinoma.</p><p><b>METHODS</b>Sixty-six patients with advanced gastric carcinoma were randomized into two groups. Patients in the treatment group (34 patients) received chemotherapy of DCF (docetaxel/cisplatin/5-fluorouracil) regimen combined with Chinese herbal medicine, and patients in the control group (32 patients) were treated with chemotherapy of the same regimen alone.</p><p><b>RESULTS</b>No significant difference between the two groups was found in response rate (55.9% versus 50.0%), clinical benefiting rate (85.3% versus 81.3%) and half year survival rate (82.4% versus 65.6%); but the 1-year survival rate in the treatment group was superior to that in the control group (52.9% versus 25.0% , P < 0.05). As for the adverse reactions, significant difference between the two groups was shown in incidence of leucopenia, nausea and vomiting, mucosa reaction and fatigue, these reactions occurred lesser in the treatment group (P< 0.05).</p><p><b>CONCLUSION</b>Although treatment of ICWM for advanced gastric carcinoma cannot improve response rate, it could alleviate the adverse reactions of the treatment, improve quality of life and prolong the survival rate in patients.</p>